Last reviewed · How we verify
NCT06749470: JOYS
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan Capsules
Phase 4 trial testing Jieyu Chufan Capsules in Major Depressive Disorder (MDD) in 480 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Central South University |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 480 |
| Start date | 22 December 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Jieyu Chufan Capsules — full drug profile →
- Jieyu Chufan Capsules simulant — full drug profile →
Conditions studied
- Major Depressive Disorder (MDD) — all drugs for Major Depressive Disorder (MDD) →
Sponsor
Central South University
Who can join
Adults 18 to 65, any sex, with Major Depressive Disorder (MDD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy of Jieyu Chufan Capsules, with placebo as the control, in combination with SSRIs in patients with moderate and severe depression. To observe the safety of Jieyu Chufan Capsules and its effects in improving the side effects of SSRIs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06749470
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Major Depressive Disorder (MDD)
Currently open trials in the same condition.
- NCT07396272 — A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression · Phase 2 · recruiting
- NCT07226661 — Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder · Phase 2 · recruiting
- NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
- NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
- NCT07294924 — Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements · recruiting
Other Central South University trials
Trials by the same sponsor.
- NCT07444463 — Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications · NA · not yet recruiting
- NCT07446478 — TIS for Improving Cognitive Impairment Associated With Schizophrenia · NA · not yet recruiting
- NCT07045142 — Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients · Phase 3 · recruiting
- NCT07066813 — Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces · recruiting
- NCT07063901 — Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06749470 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central South University
- Last refreshed: 27 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06749470.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing